New and Emerging Targeted Therapies for Patients With DLBCL

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including:

Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL  Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice  Key Ongoing Trials of new and novel agents in DLBCL  Key Presentations/Results at EHA 2026 in DLBCL

Presenters: 

Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Cancer Center
Weill Cornell University
New York, New York

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum-University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4gmyoS7

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.